Annals of Clinical and Experimental NeurologyAnnals of Clinical and Experimental Neurology2075-54732409-2533Research Center of Neurology18110.17816/psaic181UnknownMyeloproliferative diseases and ischemic strokeTanashyanMarine M.<p>D. Sci. (Med.), Prof., Corresponding member of RAS, Deputy Director for science, Head, 1<sup>st</sup> Neurological department</p>angionev@gmail.comhttps://orcid.org/0000-0002-5883-8119KuznetsovaPolina I.<p>Cand. Sci. (Med.), neurologist, researcher, 1<sup>st</sup> Neurology department</p>angionev@gmail.comhttps://orcid.org/0000-0002-4626-6520LagodaOlga V.angionev@gmail.comShabalinaAlla A.angionev@gmail.comSubortsevaI. N.angionev@gmail.comMelikyanA. L.angionev@gmail.comResearch Center of NeurologyResearch Center of Hematology, Ministry of Health0906201482414501022017Copyright © 2014, Tanashyan M.M., Kuznetsova P.I., Lagoda O.V., Shabalina A.A., Subortseva I.N., Melikyan A.L.2014<p>Myeloproliferative diseases (MPD) comprise a group of clonalpathology resulting from genetic alterations at a stem cell level.WHO (2008) divides MPD into several classical forms polycythemiavera, essential thrombocytemia, and primary myelofibrosis.Haemorheologic and haemostatic disturbances have beenwidely accepted as a significant (in some cases primary) cause ofacute and/or chronic cerebrovascular disease. A pre-existing MPDmay potentiate and accelerate the development of circulatoryalterations, including those occurring in the brain tissue, leading toischemic stroke. The present article comprises a literature reviewon this uncommon pathology, as well as a clinical presentation of astroke case in a patient with underlying MPD (Vaquez disease).</p>myeloproliferative diseasesischemic strokehemorheologyhematologyмиелопролиферативные заболеванияишемический инсультгемореологиягематология[Инсульт: диагностика, лечение, профилактика. Под. ред. З.А Суслиной, М.А. Пирадова. Москва. 2008; 288.][Суслина З.А., Танашян М.М., Ионова В.Г. Ишемический инсульт: кровь, сосудистая стенка, антитромботическая терапия. М., 2005; 248.][Танашян М.М. Гемостаз, гемореология и атромбогенная активность сосудистой стенки в ангионеврологии. Анн. клин. и эксперим. неврол. 2007; 2(1): 29–33.][Arellano-Rodrigo E., Alvarez-Larran A., Reverter J.C. et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006; 91: 169–175.][Barbui T., Finazzi G., Carobbio A. et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012; 120: 5128–5133.][Brill A., Fuchs T.A., Savchenko A.S. et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 2012; 10: 136–144.][Brinkmann V., Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol. 2001; 5: 577–582.][Carobbio A., Thiele J., Passamonti F. et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011; 117: 5857–5859.][Cella G., Marchetti M., Vianello F. et al. Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thromb Haemost. 2010; 104: 151–156.][De Stefano V., Za T., Rossi E. et al. GIMEMA CMD-Working Party Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008; 93(3): 372–380.][Di Nisio M., Barbui T., Di Gennaro L. et al. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007; 136:249–259.][Falanga A., Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematology. Education Program of the American Society of Hematology 2012. 2012; 571–581.][Goette N.P., Lev P.R., Heller P.G. et al. Monocyte IL-2Ralpha expression is associated with thrombosis and the JAK2V617F mutation in myeloproliferative neoplasms. Cytokine. 2010; 51: 67–72.][Hebbel R.P., Boogaerts M.A., Eaton J.W., Steinberg M.H. Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Eng J Med. 1980; 302: 992–995.][Jensen M.K., De NullyBrown P., Lund B.V. et al. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol. 2000; 110:116–124.][Kesler A., Ellis M.H., Manor Y. et al. Neurological complications of essential thrombocytosis (ET). Acta Neurol Scand. 2000: 102: 299–302.][17 Klampfl T., Gisslinger H., Harutyunyan A.S. et.al. Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. N Engl J Med. 2013; 369: 2679–2690.][Nangalia J., Massie C.E., Baxter E.J. et al. Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2. N Engl J Med. 2013; 369: 2391–2405.][Nazabal E.R., Lopez J.M., Perez P.A., Corral P.R. Chorea disclosing deterioration of polycythaemia vera. Postgrad Med J. 2000; 76:658–659.][Pearson T.C., Path F.R.C. Hemorrheologic considerations in the pathogenesis of vascular occlusive events in polycythaemia vera. Semin Thromb Hemost. 1997; 23: 433–439.][Semeraro F., Ammollo C.T., Morrissey J.H. et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood. 2011; 118:1952–1961.][Sozer S., Fie. M.L., Schiano T. et al. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009; 113: 5246–5249.][Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005; 23(33): 8520–8530.][Tefferi A., Thiele J., Orazi A. et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis:Recommendations from an ad hoc international expert panel. Blood. 2007; 110: 1092–1097.][Wautier M.P., Nemer W., Gane P. et al. Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha S chain and Lu/BCAM. Blood. 2007; 110:894–901.][Wautier J.L., Paton R.C., Wautier M.P. et al. Increased adhesion of erythrocytes to endothelial cells in diabetes mellitus and its relation to vascular complications. N Eng J Med. 1981; 305: 237–242.][Varricchio L., Mancini A., Migliaccio A.R. Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis. Expert Rev Hematol. Author manuscript; 2009; 2(3): 315–334.]